Advertisement

Topics

Aranesp® (darbepoetin alfa) Company Profile

03:46 EST 15th December 2018 | BioPortfolio

Aranesp® (darbepoetin alfa) is approved for the treatment of anemia associated with chronic kidney disease and chemotherapy.


News Articles [73 Associated News Articles listed on BioPortfolio]

Human medicines European public assessment report (EPAR): Aranesp, darbepoetin alfa, Revision: 40, Authorised

Japan approves first darbepoetin alfa biosimilar

Japan-based Kyowa Hakko Kirin announced on 16 August 2018 that it had gained Japanese approval for its darbepoetin alfa biosimilar.

Two darbepoetin alfa biosimilars submitted to Japan’s MHLW

Two South Korean firms have announced that they have submitted applications for approval of their proposed darbepoetin alfa biosmilars to Japan’s regulatory agency, the Ministry for Health Labour an...

Study tests daprodustat, darbepoetin alfa in CKD-related anemia

Researchers conducted a late-stage study in Japan to determine the efficacy of GlaxoSmithKline's daprodustat, taken orally, c -More- 

World First Korea Darbepoetin Biosimilar Approval To Speed CKD's Global Entry?

With a global first marketing authorization for its darbepoetin biosimilar in South Korea, Chong Kun Dang aims to speed up...   

Human medicines European public assessment report (EPAR): Pergoveris, follitropin alfa / lutropin alfa, Revision: 12, Authorised

New Zealand to fund only biosimilar epoetin alfa

New Zealand will stop funding the brand-name epoetin alfa biological Eprex and, in future, will only fund the biosimilar epoetin alfa Binocrit.

Epoetin Alfa Biosimilar Launched in United States at Discounted Cost

Epoetin alfa-epbx (Retacrit), the biosimilar to epoetin alfa (Procrit/Epogen) has been launched in the United States at a significant discount.

Drugs and Medications [57 Associated Drugs and Medications listed on BioPortfolio]

Ribavirin [Aurobindo Pharma Limited]

These highlights do not include all the information needed to use ribavirin safely and effectively. See full prescribing information for ribavirin tablets. Ribavirin Tablets Initial U.S. Approval: 200...

Aranesp [AMGEN INC]

These highlights do not include all the information needed to use Aranesp safely and effectively. See full prescribing information for Aranesp. Aranesp(darbepoetin alfa)injection, for intravenous or s...

Ribavirin [Sandoz Inc]

These highlights do not include all the information needed to use RIBAVIRIN TABLETS safely and effectively. See full prescribing information for RIBAVIRIN TABLETS. Ribavirin Tablets, oralInitial U.S. ...

Ribavirin [Cadila Healthcare Limited]

These highlights do not include all the information needed to use ribavirin safely and effectively. See full prescribing information for ribavirin. Initial U.S. Approval: 2002

Ribavirin [Zydus Pharmaceuticals (USA) Inc.]

These highlights do not include all the information needed to use ribavirin safely and effectively. See full prescribing information for ribavirin. Initial U.S. Approval: 2002

PubMed Articles [47 Associated PubMed Articles listed on BioPortfolio]

Protective effects of Tadalafil and darbepoetin against ischemia - reperfusion injury in a rat testicular torsion model.

To evaluate protective effects of darbepoetin and tadalafil against ischemiareperfusion injury in ipsilateral and contralateral testicle.

Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis.

For patients with anemia undergoing hemodialysis, erythropoiesis-stimulating agents (ESAs) are typically dosed via precise algorithms. Using one such algorithm, we assessed the maintenance of hemoglob...

Ovarian stimulation with corifollitropin alfa followed by hp-hMG compared to hp-hMG in patients at risk of poor ovarian response undergoing ICSI: A randomized controlled trial.

To compare the results of two ovarian stimulation protocols for IVF in patients at risk of poor ovarian response: corifollitropin alfa followed by hp-hMG versus daily administration of hp-hMG. We inte...

Correction to: Andexanet Alfa: First Global Approval.

The article Andexanet Alfa: First Global Approval, written by Young-A Heo, was originally published Online First without open access.

An easy-to-use baseline scoring system to predict response to peginterferon alfa-2a in patients with chronic hepatitis B in resource-limited settings.

Approximately one-third of patients have durable responses after finite (48-week) treatment with peginterferon alfa-2a. The ability to identify patients likely to respond would be particularly useful ...

Clinical Trials [938 Associated Clinical Trials listed on BioPortfolio]

Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer

The purpose of this study is to determine whether or not Aranesp® (Darbepoetin Alfa), administered every fourth week, is effective in the treatment of blood shortage (anemia) compared to ...

Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy

This study will compare the efficacy (non-inferiority) of darbepoetin alfa (Aranesp®) extended dose schedule administration (EDS) versus darbepoetin alfa administered once per week (QW) i...

Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced

The purpose of this study is to evaluate the response rate obtained in an heterogeneous oncologic population treated by chemotherapy, and either by Darbepoetin alfa classic treatment or by...

A Study Comparing Two Different PROCRIT� Doses to a Dose of ARANESP� in Anemic Cancer Patients Receiving Chemotherapy

The purpose of this study is to compare hemoglobin response rates between two PROCRIT (epoetin alfa) doses and ARANESP (darbepoetin alfa) in anemic cancer patients receiving chemotherapy.

Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation

The purpose of this study is to find out if Darbepoetin alfa is effective in treating low red blood cell levels after allogeneic stem cell transplant. Darbepoetin alfa has been shown to h...

Companies [26 Associated Companies listed on BioPortfolio]

Aranesp® (darbepoetin alfa)

Aranesp® (darbepoetin alfa) is approved for the treatment of anemia associated with chronic kidney disease and chemotherapy.

Aranesp

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of...

Alfa Scientific Designs, Inc.

Alfa Scientific Designs, Inc. is a leader in the development and manufacture of rapid, immunoassay, point-of-care tests. As a minority, woman-owned, small business, ALFA offers a ...

Assisted Living Federation of America (ALFA)

The Assisted Living Federation of America (ALFA) is the largest national association exclusively dedicated to professionally managed assisted living communities and the seniors an...

Alfa Laval

Alfa Laval is a leading global provider of specialized products and engineered solutions. Our equipment, systems and services are dedicated to helping customers to optimize the performance of their pr...

More Information about "Aranesp® (darbepoetin alfa)" on BioPortfolio

We have published hundreds of Aranesp® (darbepoetin alfa) news stories on BioPortfolio along with dozens of Aranesp® (darbepoetin alfa) Clinical Trials and PubMed Articles about Aranesp® (darbepoetin alfa) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aranesp® (darbepoetin alfa) Companies in our database. You can also find out about relevant Aranesp® (darbepoetin alfa) Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...


Corporate Database Quicklinks



Searches Linking to this Company Record